How to Use the USP–NF Errata Table

  • Searching: Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    • For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    • A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
  • Sorting: Click on any blue column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    • For example, page 2178 will come before page 74 on a page sort.
  • Downloading: You can download the Errata table in Comma-separated Value (.csv) or Excel format (.xls). The download will include all Errata from the database.
  • Printing: The table will print the view of the data as it has been filtered or sorted. To print a table of all Errata in the database, clear any keyword searches you have applied and select “Show: All”.
Monograph Title Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
ACETAMINOPHEN SUPPOSITORIES ASSAY/Procedure USP37–NF32 1567 01-Jun-2014 USP38–NF33 USP38–NF33
Line 6 of Sample stock solution: Change
add 30 mL of hexane,
to:
add 30 mL of solvent hexane,
AND
Line 10 of Sample stock solution: Change
wash the hexane
to:
wash the solvent hexane

Line 6 of Sample stock solution: Change
add 30 mL of hexane,
to:
add 30 mL of solvent hexane,
AND
Line 10 of Sample stock solution: Change
wash the hexane
to:
wash the solvent hexane

ALCOHOL IN DEXTROSE INJECTION ASSAY/Dextrose USP37–NF32 1637 01-Jun-2014 USP38–NF33 USP38–NF33
Line 15 of Analysis: Change
A = length of the polarimeter tube (mm)
to:
A = 100 mm divided by the length of the polarimeter tube (mm)

Line 15 of Analysis: Change
A =
length of the polarimeter tube (mm)

to:
A = 100 mm divided by the length of the polarimeter tube (mm)

ALUMINA, MAGNESIA, CALCIUM CARBONATE, AND SIMETHICONE CHEWABLE TABLETS ASSAY/Magnesium Hydroxide USP37–NF32 1674 01-Jun-2014 USP38–NF33 USP38–NF33
Line 5 of Magnesium stock solution: Change
Transfer 2.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 20 μg/mL of magnesium (Mg)
to:
Transfer 1.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 10 μg/mL of magnesium (Mg)

Line 5 of Magnesium stock solution: Change
Transfer 2.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 20 μg/mL of magnesium (Mg)

to:
Transfer 1.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 10 μg/mL of magnesium (Mg)

ALUMINUM CHLOROHYDRATE SOLUTION ASSAY/Procedure 4 USP37–NF32 1686 01-Jun-2014 USP38–NF33 USP38–NF33
Line 2 of Analysis: Change
anhydrous aluminum dichlorohydrate
to:
anhydrous aluminum chlorohydrate

Line 2 of Analysis: Change
anhydrous aluminum dichlorohydrate
to:
anhydrous aluminum chlorohydrate

AMINOSALICYLATE SODIUM ASSAY/Procedure USP37–NF32 1745 01-Jun-2014 USP38–NF33 USP38–NF33
Line 15 of Analysis: Change
CU = concentration of aminosalicylate in the Sample solution (mg/mL)
to:
CU = concentration of Aminosalicylate Sodium in the Sample solution (mg/mL)

Line 15 of Analysis: Change
CU = concentration of aminosalicylate in the Sample solution (mg/mL)

to:
CU = concentration of Aminosalicylate Sodium in the Sample solution (mg/mL)

AMIODARONE HYDROCHLORIDE IMPURITIES/Organic Impurities/Procedure 1 USP37–NF32 1750 01-Jun-2014 USP38–NF33 USP38–NF33
Line 3 of Acceptance criteria: Change
Standard solution B is not more intense
to:
the Sample solution is not more intense

Line 3 of Acceptance criteria: Change
Standard solution B is not more intense
to:
the Sample solution is not more intense

ATROPINE SULFATE IMPURITIES First Supplement to USP37–NF32 6591 01-Jun-2014 USP38–NF33 USP38–NF33
Row 6 of Column 1 of Table 2: Change
Hyoscyamine related compound Ae
to:
Hyoscyamine related compound A
AND
Delete footnote e
AND
Reletter the following footnotes in both the table and footnote definitions:
f to e
g to f

Row 6 of Column 1 of Table 2: Change
Hyoscyamine related compound Ae
to:
Hyoscyamine related compound A
AND
Delete footnote e
AND
Reletter the following footnotes in both the table and footnote definitions:
f to e
g to f

CARBAMAZEPINE EXTENDED-RELEASE TABLETS ASSAY/Procedure USP37–NF32 2123 01-Jun-2014 USP38–NF33 USP38–NF33
Line 2 of Sample stock solution B: Change
Standard stock solution
to:
Sample stock solution A

Line 2 of Sample stock solution B: Change
Standard stock solution
to:
Sample stock solution A

CHLOROXYLENOL IMPURITIES/Organic Impurities USP37–NF32 2308 01-Jun-2014 USP38–NF33 USP38–NF33
Line 12 of Analysis: Change
CS = concentration of 3,5-dimethylphenol or chloroxylenol related compound A in the Standard solution (mg/mL)
to:
CS = concentration of 3,5-dimethylphenol or USP Chloroxylenol Related Compound A RS in the Standard solution (mg/mL)

Line 12 of Analysis: Change
CS = concentration of 3,5-dimethylphenol or chloroxylenol related compound A in the Standard solution (mg/mL)
to:
CS = concentration of 3,5-dimethylphenol or USP Chloroxylenol Related Compound A RS in the Standard solution (mg/mL)

CHLOROXYLENOL ASSAY/Procedure USP37–NF32 2308 01-Jun-2014 USP38–NF33 USP38–NF33
Line 12 of Analysis: Change
CS = concentration of chloroxylenol in the Standard solution (mg/mL)
to:
CS = concentration of USP Chloroxylenol RS in the Standard solution (mg/mL)

Line 12 of Analysis: Change
CS = concentration of chloroxylenol in the Standard solution (mg/mL)
to:
CS = concentration of USP Chloroxylenol RS in the Standard solution (mg/mL)

CIPROFLOXACIN EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2 First Supplement to USP37–NF32 6619 01-Jun-2014 USP38–NF33 USP38–NF33
Line 1 of Standard solution: Change
0.56 mg/mL of USP Ciprofloxacin Hydrochloride RS in Medium
to:
0.62 mg/mL of USP Ciprofloxacin Hydrochloride RS in Medium
AND
Line 8 of Analysis: Change
CS = concentration of ciprofloxacin in the Standard solution (mg/mL)
to:
CS = concentration of ciprofloxacin hydrochloride in the Standard solution (mg/mL)

Line 1 of Standard solution: Change
0.56 mg/mL of USP Ciprofloxacin Hydrochloride RS in Medium
to:
0.62 mg/mL of USP Ciprofloxacin Hydrochloride RS in Medium
AND
Line 8 of Analysis: Change
CS = concentration of ciprofloxacin in the Standard solution (mg/mL)
to:
CS = concentration of ciprofloxacin hydrochloride in the Standard solution (mg/mL)

CODEINE PHOSPHATE ORAL SOLUTION ASSAY/Procedure USP37–NF32 2451 01-Jun-2014 USP38–NF33 USP38–NF33
Line 6 of Analysis: Change
Result = (RU/RS) × (CS/CU) × 100
to:
Result = (RU/RS) × (CS/CU) × (Mr1/Mr2) × 100
AND
After CU in definition list: Add
Mr1 = molecular weight of codeine phosphate hemihydrate, 406.37
Mr2 = molecular weight of anhydrous codeine phosphate, 397.37

Line 6 of Analysis: Change
Result = (RU/RS) × (CS/CU) × 100
to:
Result = (RU/RS) × (CS/CU) ×
(Mr1/Mr2) ×

100

AND
After CU in definition list: Add
Mr1 = molecular weight of codeine phosphate hemihydrate, 406.37
Mr2 = molecular weight of anhydrous codeine phosphate, 397.37

DAPSONE TABLETS IDENTIFICATION/B. Ultraviolet Absorption <197U> USP37–NF32 2514 01-Jun-2014 USP38–NF33 USP38–NF33
Line 1 of Sample solution:
Delete Nominally 0.01 μg/mL prepared as follows.

Line 1 of Sample solution:
Delete Nominally 0.01 μg/mL prepared as follows.

DESCRIPTION AND SOLUBILITY Sodium Acetate USP37–NF32 1525 01-Jun-2014 USP38–NF33 USP38–NF33
Line 7: Change
transfer liquid.
to:
transfer ligand.

Line 7: Change
transfer liquid.
to:
transfer ligand.

DESCRIPTION AND SOLUBILITY Racemethionine USP37–NF32 1523 01-Jun-2014 USP38–NF33 USP38–NF33
Line 6: Change
flavors and frangrance.
to:
flavors and fragrance.

Line 6: Change
flavors and frangrance.
to:
flavors and fragrance.

DESCRIPTION AND SOLUBILITY Potassium Alginate USP37–NF32 1520 01-Jun-2014 USP38–NF33 USP38–NF33
Line 6: Change
suspending and/or viscosity agent.
to:
suspending and/or viscosity-increasing agent.

Line 6: Change
suspending and/or viscosity agent.
to:
suspending and/or viscosity-increasing agent.

DESCRIPTION AND SOLUBILITY Lauric Acid USP37–NF32 1506 01-Jun-2014 USP38–NF33 USP38–NF33
Line 4: Change
emulsifying and/or solubilizing agent; tablet and/or capsule lubricant.
to:
emulsifying agent; lubricant.

Line 4: Change
emulsifying and/or solubilizing agent; tablet and/or capsule lubricant.

to:
emulsifying agent; lubricant.

DESCRIPTION AND SOLUBILITY Carmellose USP37–NF32 1486 01-Jun-2014 USP38–NF33 USP38–NF33
Line 4: Change
Suspending and/or viscosity increasing agent;
to:
Suspending and/or viscosity-increasing agent;

Line 4: Change
Suspending and/or viscosity increasing agent;
to:
Suspending and/or viscosity-increasing agent;

DIPHENHYDRAMINE CITRATE AND IBUPROFEN TABLETS IMPURITIES/Limit of Ibuprofen Related Compound C USP37–NF32 2651 01-Jun-2014 USP38–NF33 USP38–NF33
Line 7 of Analysis: Change
RU = peak area ratio of ibuprofen to valerophenone from the Sample solution
RS = peak area ratio of ibuprofen to valerophenone from the Standard solution
to:
RU = peak area ratio of ibuprofen related compound C to valerophenone from the Sample solution
RS = peak area ratio of ibuprofen related compound C to valerophenone from the Standard solution

Line 7 of Analysis: Change
RU = peak area ratio of ibuprofen to valerophenone from the Sample solution
RS = peak area ratio of ibuprofen to valerophenone from the Standard solution
to:
RU = peak area ratio of ibuprofen related compound C to valerophenone from the Sample solution
RS = peak area ratio of ibuprofen related compound C to valerophenone from the Standard solution

DOXEPIN HYDROCHLORIDE ORAL SOLUTION ASSAY/Procedure USP37–NF32 2713 01-Jun-2014 USP38–NF33 USP38–NF33
Line 1 of Standard solution: Change
Dilute 4.0 of Standard stock solution
to:
Dilute 4.0 mL of Standard stock solution

Line 1 of Standard solution: Change
Dilute 4.0 of Standard stock solution
to:
Dilute 4.0 mL of Standard stock solution

ECHINACEA ANGUSTIFOLIA ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5343 01-Jun-2014 USP38–NF33 USP38–NF33
Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea angustifolia Extract RS

Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea angustifolia Extract RS

ECHINACEA PALLIDA ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5353 01-Jun-2014 USP38–NF33 USP38–NF33
Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea pallida Extract RS

Line 5: Change
USP Powdered Echinacea purpurea Extract RS

to:
USP Powdered Echinacea pallida Extract RS

ESCITALOPRAM TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2 USP37–NF32 2852 01-Jun-2014 USP38–NF33 USP38–NF33
Line 3 of Buffer: Change
phosphoric
to:
phosphoric acid

Line 3 of Buffer: Change
phosphoric
to:
phosphoric acid

FOSPHENYTOIN SODIUM INJECTION ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 3096 01-Jun-2014 USP38–NF33 USP38–NF33
Before USP Fosphenytoin Sodium RS: Add
USP Endotoxin RS

Before USP Fosphenytoin Sodium RS: Add
USP Endotoxin RS

GADOPENTETATE DIMEGLUMINE INJECTION IDENTIFICATION/B. USP37–NF32 3113 01-Jun-2014 USP38–NF33 USP38–NF33
Line 2: Change
364.8 nm
to:
368.4 nm

Line 2: Change
364.8 nm
to:
368.4 nm

GRISEOFULVIN CAPSULES PERFORMANCE TESTS/Uniformity of Dosage Units <905>/Procedure for content uniformity USP37–NF32 3196 01-Jun-2014 USP38–NF33 USP38–NF33
Line 6 of Analysis: Change
Result = (AU/AS) × (CS/CU) × P × 100
to:
Result = (AU/AS) × (CS/CU) × P × F × 100
AND
After P in definition list: Add
F = conversion factor, 0.001 mg/μg

Line 6 of Analysis: Change
Result = (AU/AS) × (CS/CU) × P × 100
to:
Result = (AU/AS) × (CS/CU) × P × F × 100
AND
After P in definition list: Add
F = conversion factor, 0.001 mg/μg

GRISEOFULVIN TABLETS ASSAY/Procedure USP37–NF32 3198 01-Jun-2014 USP38–NF33 USP38–NF33
Line 13 of Analysis: Change
P = potency of griseofulvin in USP Griseofulvin RS (μg/mL)
to:
P = potency of griseofulvin in USP Griseofulvin RS (μg/mg)

Line 13 of Analysis: Change
P = potency of griseofulvin in USP Griseofulvin RS (μg/mL)
to:
P = potency of griseofulvin in USP Griseofulvin RS (μg/mg)

HEXACHLOROPHENE LIQUID SOAP IDENTIFICATION/B. USP37–NF32 3231 01-Jun-2014 USP38–NF33 USP38–NF33
Line 1 of Analysis: Change
Sample solution
to:
Sample

Line 1 of Analysis: Change
Sample solution
to:
Sample

HOLY BASIL LEAF COMPOSITION/Content of Triterpenes USP37–NF32 5454 01-Jun-2014 USP38–NF33 USP38–NF33
Line 4 of Standard solution B: Change
0.45-μL
to:
0.45-μm

Line 4 of Standard solution B: Change
0.45-μL
to:
0.45-μm

HYDROCHLOROTHIAZIDE TABLETS IMPURITIES/Organic Impurities USP37–NF32 3247 01-Jun-2014 USP38–NF33 USP38–NF33
Line 11 of Analysis: Change
CU = concentration of the Sample solution (μg/mL)
to:
CU = nominal concentration of hydrochlorothiazide in the Sample solution (μg/mL)

Line 11 of Analysis: Change
CU = concentration of the Sample solution (μg/mL)
to:
CU = nominal concentration of hydrochlorothiazide in the Sample solution (μg/mL)

LAMIVUDINE AND ZIDOVUDINE TABLETS IMPURITIES/Organic Impurities USP37–NF32 3484 01-Jun-2014 USP38–NF33 USP38–NF33
Line 12 of Analysis: Change
unidentified impurity
to:
unspecified impurity
AND
Line 19 of Analysis: Change
unidentified impurities
to:
unspecified impurities

Line 12 of Analysis: Change
unidentified impurity
to:
unspecified impurity
AND
Line 19 of Analysis: Change
unidentified impurities
to:
unspecified impurities

LINDANE CREAM ASSAY/Procedure/Chromatographic system/Temperatures USP37–NF32 3561 01-Jun-2014 USP38–NF33 USP38–NF33
After the Injection port subsection: Add a new subsection
Detector: 250°

After the Injection port subsection: Add a new subsection
Detector: 250°

MAPROTILINE HYDROCHLORIDE TABLETS PERFORMANCE TESTS/Dissolution <711> USP37–NF32 3655 01-Jun-2014 USP38–NF33 USP38–NF33
Line 3 of Analysis: Change
Determine the labeled amount of maprotiline hydrochloride
to:
Determine the percentage of the labeled amount of maprotiline hydrochloride

Line 3 of Analysis: Change
Determine the labeled amount of maprotiline hydrochloride

to:
Determine the percentage of the labeled amount of maprotiline hydrochloride

METHADONE HYDROCHLORIDE ORAL SOLUTION OTHER COMPONENTS USP37–NF32 3744 01-Jun-2014 USP38–NF33 USP38–NF33
Line 3 of Alcohol Determination: Change
gas–liquid chromatographic procedure
to:
gas chromatographic procedure

Line 3 of Alcohol Determination: Change
gas–liquid chromatographic procedure

to:
gas chromatographic procedure

MICONAZOLE INJECTION IDENTIFICATION/A./Chromatographic system USP37–NF32 3831 01-Jun-2014 USP38–NF33 USP38–NF33
Line 1 of Spray reagent: Change
(Dragendorff’s reagent)
to:
(Dragendorff’s TS)

Line 1 of Spray reagent: Change
(Dragendorff’s reagent)

to:
(Dragendorff’s TS)

NYSTATIN DEFINITION USP37–NF32 4035 01-Jun-2014 USP38–NF33 USP38–NF33
Line 6: Change
extemporaneous solution
to:
extemporaneous preparation

Line 6: Change
extemporaneous solution
to:
extemporaneous preparation

OLMESARTAN MEDOXOMIL CHEMICAL INFORMATION USP37–NF32 4057 01-Jun-2014 USP38–NF33 USP38–NF33
Line 3 of the chemical name: Change
methyl ester
to:
methyl ester;
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate

Line 3 of the chemical name: Change
methyl ester
to:
methyl ester;
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate

OMEPRAZOLE ORAL SUSPENSION ASSAY/Procedure USP37–NF32 4067 01-Jun-2014 USP38–NF33 USP38–NF33
Line 2 of Solution A: Change
with dilute phosphoric acid
to:
with dilute sodium hydroxide

Line 2 of Solution A: Change
with dilute phosphoric acid
to:
with dilute sodium hydroxide

ORANGE OIL ASSAY/Total Aldehyde Content USP37–NF32 6091 01-Jun-2014 USP38–NF33 USP38–NF33
Line 1 of Sample: Change
5 mL of Oil
to:
5 mL of Orange Oil, accurately weighed

Line 1 of Sample: Change
5 mL of Oil
to:
5 mL of Orange Oil, accurately weighed

OXCARBAZEPINE TABLETS IMPURITIES USP37–NF32 4119 01-Jun-2014 USP38–NF33 USP38–NF33
Row 5 of Column 1 of Table 1: Change
Methoxydibenzazepineb
to:
Methoxycarbamazepineb

Row 5 of Column 1 of Table 1: Change
Methoxydibenzazepineb
to:
Methoxycarbamazepineb

OXCARBAZEPINE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2 USP37–NF32 4119 01-Jun-2014 USP38–NF33 USP38–NF33
Line 4 of Standard solution: Change
µg/mL, where L is the label claim in mg/Tablet.
to:
mg/mL, where L is the label claim in mg/Tablet.

Line 4 of Standard solution: Change
µg/mL, where L is the label claim in mg/Tablet.

to:
mg/mL, where L is the label claim in mg/Tablet.

PHENYTOIN SODIUM INJECTION OTHER COMPONENTS/Alcohol and Propylene Glycol Content First Supplement to USP37–NF32 6684 01-Jun-2014 USP38–NF33 USP38–NF33
Line 3 of Standard solution: Change
Internal standard stock solution
to:
Internal standard solution

Line 3 of Standard solution: Change
Internal standard stock solution
to:
Internal standard solution

POWDERED DECAFFEINATED GREEN TEA EXTRACT SPECIFIC TESTS USP37–NF32 5438 01-Jun-2014 USP38–NF33 USP38–NF33
Line 5 of Analysis in Limit of Gallic Acid: Change
Separately calculate the percentages of gallic acid
to:
Calculate the percentage of gallic acid
AND
Line 5 of Analysis in Limit of Caffeine: Change
Separately calculate the percentages of caffeine
to:
Calculate the percentage of caffeine

Line 5 of Analysis in Limit of Gallic Acid: Change
Separately calculate the percentages of gallic acid
to:
Calculate the percentage of gallic acid
AND
Line 5 of Analysis in Limit of Caffeine: Change
Separately calculate the percentages of caffeine
to:
Calculate the percentage of caffeine

POWDERED DECAFFEINATED GREEN TEA EXTRACT COMPOSITION/Content of Polyphenols/Chromatographic system USP37–NF32 5438 01-Jun-2014 USP38–NF33 USP38–NF33
Line 1 of Column: Change
4.6-mm 6 25-cm;
to:
4.6-mm × 25-cm;

Line 1 of Column: Change
4.6-mm 6 25-cm;
to:
4.6-mm × 25-cm;

POWDERED ECHINACEA ANGUSTIFOLIA ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5346 01-Jun-2014 USP38–NF33 USP38–NF33
Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea angustifolia Extract RS

Line 5: Change
USP Powdered Echinacea purpurea Extract RS

to:
USP Powdered Echinacea angustifolia Extract RS

POWDERED ECHINACEA ANGUSTIFOLIA EXTRACT ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5350 01-Jun-2014 USP38–NF33 USP38–NF33
Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea angustifolia Extract RS

Line 5: Change
USP Powdered Echinacea purpurea Extract RS

to:
USP Powdered Echinacea angustifolia Extract RS

POWDERED ECHINACEA PALLIDA ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5356 01-Jun-2014 USP38–NF33 USP38–NF33
Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea pallida Extract RS

Line 5: Change
USP Powdered Echinacea purpurea Extract RS

to:
USP Powdered Echinacea pallida Extract RS

POWDERED ECHINACEA PALLIDA EXTRACT ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5359 01-Jun-2014 USP38–NF33 USP38–NF33
Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea pallida Extract RS

Line 5: Change
USP Powdered Echinacea purpurea Extract RS

to:
USP Powdered Echinacea pallida Extract RS

POWDERED ECHINACEA PURPUREA EXTRACT COMPOSITION USP37–NF32 5371 01-Jun-2014 USP38–NF33 USP38–NF33
Line 14 of Analysis in Content of Total Phenols: Change
CS = concentration of the relevant analyte in the corresponding Standard solution
CU = concentration of Echinacea purpurea in the Sample solution (mg/mL)
to:
CS = concentration of the relevant analyte in the corresponding Standard solution (mg/mL)
CU = concentration of Powdered Echinacea purpurea Extract in the Sample solution (mg/mL)
AND
Line 20 of Analysis in Content of Dodecatetraenoic Acid Isobutylamides: Change
CU = concentration of Echinacea purpurea in the Sample solution (mg/mL)
to:
CU = concentration of Powdered Echinacea purpurea Extract in the Sample solution (mg/mL)

Line 14 of Analysis in Content of Total Phenols: Change
CS = concentration of the relevant analyte in the corresponding Standard solution
CU = concentration of Echinacea purpurea in the Sample solution (mg/mL)

to:
CS = concentration of the relevant analyte in the corresponding Standard solution
(mg/mL)
CU = concentration of Powdered Echinacea purpurea Extract in the Sample solution (mg/mL)

AND

Read more
POWDERED HOLY BASIL LEAF COMPOSITION/Content of Triterpenes USP37–NF32 5456 01-Jun-2014 USP38–NF33 USP38–NF33
Line 4 of Standard solution B: Change
0.45-μL
to:
0.45-μm

Line 4 of Standard solution B: Change
0.45-μL
to:
0.45-μm

XLS CSV